NDAORALCAPSULE
Approved
Apr 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
FELDENE (piroxicam) by Pfizer is clinical pharmacology pharmacodynamics piroxicam capsules are a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. First approved in 1982.
Drug data last refreshed 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FELDENE (piroxicam) is an oral NSAID capsule approved in 1982 for dysmenorrhea and postcoital contraception. It works by inhibiting prostaglandin synthetase, providing anti-inflammatory, analgesic, and antipyretic activity. The drug has a prolonged 50-hour half-life enabling once-daily dosing with steady-state reached in 7–12 days.
$29KPart D
LOE ApproachingDeclining
Minimal commercial activity and declining market presence signal limited team investment; legacy brand approaching loss of exclusivity.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Piroxicam capsules are a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of piroxicam, like that of other NSAIDs, is not completely understood but may…
Worked on FELDENE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.